跳至主要内容
临床试验/JPRN-UMIN000003699
JPRN-UMIN000003699已完成2 期

Evaluation of the usefulness of letrozole as neoadjuvant hormone therapy for postmenopausal patients with hormone receptor-positive breast cancer - Evaluation of the usefulness of letrozole as neoadjuvant hormone therapy for postmenopausal patients with hormone receptor-positive breast cancer

St. Luke's International Hospital0 个研究点目标入组 60 人开始时间: 2010年6月3日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • (1) Patients with previous treatment for the breast cancer. (2) Patients receiving drugs having a potential influence on the status of sex hormones (hormone replacement therapy, raloxifene, etc.). (However, patients after washout for at least 2 months can be enrolled.) (3) Synchronous or asynchrous bilateral breast cancer. (4) Patients with active double cancer. (5) Patients with myocardial infarction or congestive heart failure at the past history, or patients who need treatment of ischemic hear disease, arryhythmia or valvular disorder. (6) Patients within 30 days after completion of treatment with the investigational drugs. (7) Patients whom doctors judged inadequate to the enrollment of this study by other reasons.

研究者

发起方
St. Luke's International Hospital

相似试验